drugset / Trial / NCT02525796

Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism

NCT02525796

Phase 2/3 Completed 69 enrolled Brigham and Women's Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate whether blocking the mineralocorticoid receptor, alone, or in combination with the calcimimetic cinacalcet, can lower parathyroid hormone and calcium levels in primary hyperparathyroidism.

Timeline

Start
2016-01
Primary completion
2021-10-01
Completion
2021-10-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amiloride Small molecule 10 mg
Subject Eplerenone Unknown 50 mg
Background Cinacalcet Other / unclassified 30 mg